Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 55
Filter
1.
Int Immunopharmacol ; 137: 112424, 2024 Jun 14.
Article in English | MEDLINE | ID: mdl-38878486

ABSTRACT

Colorectal cancer is a major global health burden, with limited efficacy of traditional treatment modalities in improving survival rates. However, recently advances in immunotherapy has improved treatment outcomes for patients with this cancer. To address the continuing need for improved treatment efficacy, this study introduced a novel tri-specific antibody, IMT030122, that targets EpCAM, 4-1BB, and CD3. We evaluated the pharmacological efficacy and mechanism of action of IMT030122 in vitro and in vivo. In in vitro studies, IMT030122 exhibited differential binding to antigens and cells expressing EpCAM, 4-1BB, and CD3. Moreover, IMT030122 relied on EpCAM-targeted activation of intracellular CD3 and 4-1BB signaling and mediated T cell cytotoxicity specific to HCT116 colorectal cancer cells. In vivo, IMT030122 demonstrated potent anti-tumor activity, significantly inhibiting the growth of colon cancer HCT116 and MC38-hEpCAM subcutaneous grafts. Further pharmacological analysis revealed that IMT030122 recruited lymphocytes from peripheral blood into colorectal cancer tissue and exerted durable anti-tumor activity, predominantly by promoting the activation, proliferation, and differentiation of CD8T cells. Notably, IMT030122 still exhibited anti-tumor efficacy even in the presence of significantly depleted lymphocytes in colorectal cancer tissue. The potent pharmacological activity and anti-tumor effects of IMT030122 suggest it may enhance treatment efficacy and substantially extend the survival of patients with colorectal cancer in the future.

2.
Cancer Immunol Immunother ; 72(12): 4015-4030, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37863852

ABSTRACT

BACKGROUND: Additional immunotherapies are still warranted for non-responders to checkpoint inhibitors with refractory or relapsing cancers, especially for patients with "cold" tumours lacking significant immune infiltration at treatment onset. We developed XFab-α4-1BB/CD40L, a bispecific antibody targeting 4-1BB and CD40 for dendritic cell activation and priming of tumour-reactive T cells to inhibit tumours. METHODS: XFab-α4-1BB/CD40L was developed by engineering an anti-4-1BB Fab arm into a CD40L trimer based on XFab® platform. Characterisation of the bispecific antibody was performed by cell-based reporter assays, maturation of dendritic cell assays, and mixed lymphocyte reactions. The abilities of antigen-specific T-cell expansion and antitumour efficacy were assessed in syngeneic mouse tumour models. Toxicological and pharmacodynamic profiles were investigated in non-human primates. RESULTS: XFab-α4-1BB/CD40L demonstrated independent CD40 agonistic activity and conditional 4-1BB activity mediated by CD40 crosslinking, leading to dendritic cell maturation and T-cell proliferation in vitro. We confirmed the expansion of antigen-specific T cells in the vaccination model and potent tumour regression induced by the bispecific antibody alone or in combination with gemcitabine in vivo, concomitant with improved tumour-reactive T-cell infiltration. XFab-α4-1BB/CD40L showed no signs of liver toxicity at doses up to 51 mg/kg in a repeated-dose regimen in non-human primates. CONCLUSIONS: XFab-α4-1BB/CD40L is capable of enhancing antitumour immunity by modulating dendritic cell and T-cell functions via targeting 4-1BB agonism to areas of CD40 expression. The focused, potent, and safe immune response induced by the bispecific antibody supports further clinical investigations for the treatment of solid tumours.


Subject(s)
CD40 Ligand , Neoplasms , Humans , Mice , Animals , T-Lymphocytes/metabolism , Neoplasms/therapy , Neoplasms/metabolism , CD40 Antigens , Primates/metabolism , Dendritic Cells
3.
Sensors (Basel) ; 23(13)2023 Jun 21.
Article in English | MEDLINE | ID: mdl-37447636

ABSTRACT

In response to the real-time imaging detection requirements of structural defects in the R region of rib-stiffened wing skin, a defect detection algorithm based on phased-array ultrasonic imaging for wing skin with stiffener is proposed. We select the full-matrix-full-focusing algorithm with the best imaging quality as the prototype for the required detection algorithm. To address the problem of poor real-time performance of the algorithm, a sparsity-based full-focusing algorithm with symmetry redundancy imaging mode is proposed. To address noise artifacts, an adaptive beamforming method and an equal-acoustic-path echo dynamic removal scheme are proposed to adaptively suppress noise artifacts. Finally, within 0.5 s of imaging time, the algorithm achieves a detection sensitivity of 1 mm and a resolution of 0.5 mm within a single-frame imaging range of 30 mm × 30 mm. The defect detection algorithm proposed in this paper combines phased-array ultrasonic technology and post-processing imaging technology to improve the real-time performance and noise artifact suppression of ultrasound imaging algorithms based on engineering applications. Compared with traditional single-element ultrasonic detection technology, phased-array detection technology based on post-processing algorithms has better defect detection and imaging characterization performance and is suitable for R-region structural detection scenarios.


Subject(s)
Algorithms , Ultrasonics , Animals , Ultrasonography/methods , Phantoms, Imaging , Technology
4.
Sensors (Basel) ; 23(13)2023 Jun 26.
Article in English | MEDLINE | ID: mdl-37447777

ABSTRACT

The line structured light plane calibration method using a plane target cannot produce satisfactory calibration results due to inaccurate positioning of the calibrated points. Field of view noise and sensor noise affect the target light stripe extraction and camera parameter calculation during the calibration process. These factors will cause the calculation of the coordinates of the calibrated point to deviate, and thus affect the light plane calibration. To solve this problem, we propose a new method to calculate the calibrated point based on spatial geometry. Firstly, for the projection line corresponding to the feature point on the light stripe and the corresponding line on the target, a common perpendicular of these two lines above is established, and since the sum of the squares of the distances from the midpoint to the two straight lines is the smallest, the midpoint of the common perpendicular is taken as the calibrated point. Secondly, the target is moved to different positions, and the non-collinear calibrated points are calculated. Finally, the parameters of the light plane are obtained by fitting these calibrated points. This method requires only a checkerboard target, and has a simple calibration process. The experimental results show that the average error of the calibration method proposed in this paper is 0.011 mm, which is less than the 0.031 mm of the calibration method based on the plane target with cross-ratio invariant.

5.
Appl Opt ; 62(9): 2386-2393, 2023 Mar 20.
Article in English | MEDLINE | ID: mdl-37132878

ABSTRACT

Automated identification of single-pointer meter identification in substations is widely used in the construction of digital substations and it must accurately identify the value of the pointer meter. Current single-pointer meter identification methods are not universally applicable and can only identify one type of meter. In this study, we present a hybrid framework for single-pointer meter identification. First, the input image of the single-pointer meter is modeled to gain a priori knowledge, including the template image, dial position information, the pointer template image, and scale value positions. Based on a convolutional neural network to generate the input image and the template image feature points, image alignment is then applied through a feature point match to mitigate slight changes in the camera angle. Next, a pixel loss-free method of arbitrary point image rotation correction is presented for rotation template matching. Finally, by rotating the input gray mask image of the dial and matching it to the pointer template to get the optimal rotation angle, the meter value is calculated. The experimental findings demonstrate the method's effectiveness in identifying nine different types of single-pointer meters in substations with various ambient illuminations. This study provides a feasible reference for substations to identify the value of different types of single-pointer meters.

6.
Appl Opt ; 62(12): 3208-3214, 2023 Apr 20.
Article in English | MEDLINE | ID: mdl-37133171

ABSTRACT

To evaluate the assembly accuracy of rudders during the production of aerospace vehicles, a measurement method based on monocular vision is proposed in this paper. Compared with existing methods that adopt cooperative targets pasted manually, the proposed method avoids pasting cooperative targets on the surface of rudders and calibrating the original position of rudders in advance. First, we use two known position markers on the surface of the vehicle and multiple feature points of the rudder to solve the relative pose between the camera and the rudder by employing the PnP algorithm. Then, we measure the rotation angle by converting the change of the camera's pose to the rotation angle of the rudder. Finally, a tailored error compensation model is introduced into the proposed method to increase the accuracy of the measurement. Experiment results show that the average measurement absolute error of the proposed method is less than 0.08° overall, which is remarkably superior to existing methods and satisfies the requirement of practical industrial production.

7.
Cell Biol Int ; 47(9): 1519-1534, 2023 Sep.
Article in English | MEDLINE | ID: mdl-37208963

ABSTRACT

Circular RNAs (circRNAs) may be involved in tumorigenesis. Recently, the role of circRNAs in hepatocellular carcinoma (HCC) has drawn wide attention. Herein, we aimed to explore the regulation and function of hsa_circ_0005239 in the malignant biological behavior and angiogenesis of HCC, as well as the link between hsa_circ_0005239 and programmed cell death ligand 1 (PD-L1) in HCC. Quantitative real-time polymerase chain reaction (qRT-PCR) assays revealed that hsa_circ_0005239 was upregulated in HCC tumor samples and cell lines. Furthermore, a series of in vitro and in vivo assays explored the effects of hsa_circ_0005239 on biological processes involved in the development of HCC. Knockdown of hsa_circ_0005239 significantly inhibited cell migration, cell invasion, and angiogenesis in HCC, while overexpression showed the opposite effect. In the in vivo assays, hsa_circ_0005239 downregulation suppressed the growth of xenograft tumors in nude mice, which supported that hsa_circ_0005239 is a tumor promoter in HCC. Mechanistically, hsa_circ_0005239 binds to miR-34a-5p and functions as a competing endogenous RNA to modulate the expression of PD-L1. Further experiments revealed that the hsa_circ_0005239/PD-L1 axis regulates the malignant phenotypes of HCC cells through the phosphoinositide-3 kinase/protein kinase B (PI3K/Akt) signaling pathway. These results revealed the role of hsa_circ_0005239 and the hsa_circ_0005239/miR-34a-5p/PD-L1 axis in HCC, providing a potential diagnostic biomarker and therapeutic target for HCC.


Subject(s)
Carcinoma, Hepatocellular , Liver Neoplasms , MicroRNAs , Animals , Mice , Humans , RNA, Circular/genetics , Carcinoma, Hepatocellular/genetics , Carcinoma, Hepatocellular/pathology , MicroRNAs/metabolism , B7-H1 Antigen/genetics , B7-H1 Antigen/metabolism , Liver Neoplasms/genetics , Liver Neoplasms/pathology , Phosphatidylinositol 3-Kinases/metabolism , Mice, Nude , Cell Line, Tumor , Cell Movement/genetics , Cell Proliferation/genetics , Gene Expression Regulation, Neoplastic
8.
Comp Med ; 2023 Apr 01.
Article in English | MEDLINE | ID: mdl-37072182

ABSTRACT

Current follicle-stimulating hormone (FSH) drugs meet safety criteria but have suboptimal efficacy, poor patient compliance, and high cost. Alternative FSH-like drugs would help to meet the high market demand. Here, we evaluated X002, an FSH-Fc fusion protein, for bioactivity and half-life in vitro and in vivo. In all cases, the effects of X002 were compared with those of a commercially available short-acting FSH recombinant hormone. First, female Kunming mice (age, 21 to 24 d) were stimulated with pregnant mare serum gonadotropin (PMSG) for 46 h, after which naked oocytes were harvested, treated with X002 or the comparison agent at 37 °C for 4 h, and then evaluated for germinal vesicle breakdown. Second, cumulus-oocyte complexes (COC) were collected from PMSG-stimulated mice and cocultured with X002 or the comparison agent for 14 h; the COC diameters were then measured, and the expression of genes involved in COC expansion were evaluated using quantitative RT-PCR analysis. Third, to assess the pharmacokinetics of X002, female Sprague-Dawley rats (age, 6 to 8 wk) were injected subcutaneously with X002 or the comparison agent; serum samples then were collected at various times and assessed via ELISA. Fourth, to evaluate X002 pharmacodynamics, 26-d-old female Sprague-Dawley rats were treated with X002 or the comparison agent; 84 h later, the rats were stimulated with human chorionic gonadotropin (hCG). At 12 h after hCG injection, euthanasia was performed. Ovaries were removed and weighed, and serum levels of estradiol and progesterone were measured. Finally, to assess superovulation, the oocytes in the fallopian tubes were counted at 108 h after in vivo treatment of rats with X002 or the comparison agent. The data show that X002, a long-acting agent, promoted germinal vesicle breakdown and COC expansion in vitro and in vivo ovarian weight gain and superovulation to a degree similar to the short-acting comparison agent.

9.
Materials (Basel) ; 16(4)2023 Feb 08.
Article in English | MEDLINE | ID: mdl-36837050

ABSTRACT

The effect of porosity and pore size on the quasi-static compression properties and energy absorption characteristics of the steel foam was investigated in this paper. The 316L steel foams were prepared through powder metallurgy using urea as the space holder. The macrostructure of steel foam and microstructure of the pore walls were characterized, and the quasi-static compression experiments were conducted on the specimens in the axial direction at a strain rate of 10-3 s-1. The results show that the increase in porosity decreases the yield strength and plastic modulus of the steel foam but increases the densification strain of the steel foam. The yield strength of the steel foam decreases significantly when the pore size is 2.37 mm. However, the pore size has little effect on the plastic modulus. Moreover, the energy absorption per volume of the steel foam decreases with increasing porosity at the same strain. The effect of porosity on energy absorption efficiency is greater than that of pore size.

10.
Int J Mol Sci ; 23(19)2022 Oct 10.
Article in English | MEDLINE | ID: mdl-36233320

ABSTRACT

Bio-macromolecules have potential applications in cancer treatment due to their high selectivity and efficiency in hitting therapeutic targets. However, poor cell membrane permeability has limited their broad-spectrum application in cancer treatment. The current study developed highly internalizable anti-c-MET antibody Fab fusion proteins with intracellular epitope peptide chimera to achieve the dual intervention from the extracellular to intracellular targets in tumor therapy. In vitro experiments demonstrated that the fusion proteins could interfere with the disease-associated intracellular signaling pathways and inhibit the uncontrolled proliferation of tumor cells. Importantly, investigation of the underlying mechanism revealed that these protein chimeras could induce vacuolation in treated cells, thus interfering with the normal extension and arrangement of microtubules as well as the mitosis, leading to the induction of methuosis-mediated cell death. Furthermore, in vivo tumor models indicated that certain doses of fusion proteins could inhibit the A549 xenograft tumors in NOD SCID mice. This study thus provides new ideas for the intracellular delivery of bio-macromolecules and the dual intervention against tumor cell signaling pathways.


Subject(s)
Proto-Oncogene Proteins c-met , Signal Transduction , Adaptor Proteins, Signal Transducing/metabolism , Animals , Antibodies/metabolism , Epitopes , GRB2 Adaptor Protein/metabolism , Humans , Mice , Mice, SCID , Peptides/chemistry , Proto-Oncogene Proteins c-met/genetics , Proto-Oncogene Proteins c-met/metabolism
11.
Materials (Basel) ; 15(19)2022 Sep 23.
Article in English | MEDLINE | ID: mdl-36233957

ABSTRACT

High-speed steel is widely used for cutting tools due to its convenience of preparation and cost-effectiveness. Previous research has shown that deep cryogenic treatments improve the mechanical properties of high-speed steel, due to the transformation of the residual austenite and the precipitation of carbide, while few studies have researched martensitic changes. The variations in martensite multi-level microstructures in AISI M35 high-speed steel, treated over different deep cryogenic time periods, were investigated in this study. Meanwhile, the effect of these variations on the mechanical properties of the selected steel was discussed. It was found that prolonging deep cryogenic time facilitated an increase in dislocation, low-angle grain boundary, and the coincident-site lattice boundary (especially the twin boundary) of martensite. The size of the martensite block (db) and lath (dl) decreased with deep cryogenic time. However, the effect on the microstructure was limited when the cryogenic treatment time exceeded 5 h. The increase in dislocation decreased the temperature for carbide precipitation and promoted fine carbide precipitation during tempering. The refinement of martensite multi-level microstructures and the greater precipitation of fine carbides gave the tempered specimens excellent impact toughness. The impact toughness of the tempered samples undergoing deep cryogenic treatment for more than 5 h was about 32% higher than the sample without deep cryogenic treatment.

12.
Immunobiology ; 227(6): 152283, 2022 11.
Article in English | MEDLINE | ID: mdl-36198215

ABSTRACT

The claudin 18.2(CLDN18.2) antigen is highly expressed in gastric mucosa epithelial cells and frequently expressed in malignant tumors. Positive clinical outcomes have popularized claudin 18.2 as a novel cellular and antibody therapeutic. Here, we designed a bispecific antibody-ZWB67 using the XFab® platform, aimed at redirecting CD3+ effector T cells to CLDN18.2+ target cells or tissues. Physicochemical characterization, binding properties, T cell stimulatory activity, and T cell-dependent cellular cytotoxicity of ZWB67 were evaluated in dosage intervals using antigens of CD3 and target cells expressing CLDN18.2 or CD3. Then, the anti-tumor activity was assessed in humanized CD3EDG mice bearing MC-38-hCLDN18.2 tumors. Our data demonstrate that ZWB67 specifically binds to the human CD3e antigen (KD = 1.04E-08 M) and binds more strongly to CLDN18.2+ cells than to CD3+ cells (4.3- to 9.2-fold difference). ZWB67 showed good activity in the luciferase reporter system and exhibited dose-dependent activation, cytotoxicity of T cells, and cytokine release when co-cultured with CLDN18.2+ cells and CD3+ T cells. ZWB67 also exhibited high in vivo efficacy in the MC-38-hCLDN18.2 xenograft mouse model. In conclusion, the novel anti-CLDN18.2 × anti-CD3 bispecific antibody exhibited low affinity for anti-CD3, highly specific binding, potent cytotoxicity, and anti-tumor activity. These data provide a basis for future preclinical and clinical development of this therapeutic strategy.


Subject(s)
Antibodies, Bispecific , Neoplasms , Humans , Mice , Animals , CD3 Complex , Antibodies, Bispecific/pharmacology , Antibodies, Bispecific/therapeutic use , T-Lymphocytes , Neoplasms/drug therapy , Claudins
13.
Front Immunol ; 13: 847601, 2022.
Article in English | MEDLINE | ID: mdl-35300339

ABSTRACT

Background: Locoregional therapy combined with systemic therapy can further improve the prognoses for HCC. However, the efficacy of TACE combined with ICIs and TKIs for HCC and whether this triple therapy can activate systemic immune response are still unknown. Purpose: To identify the efficacy of TACE+ICIs+TKIs for unresectable hepatocellular carcinoma (uHCC) and its effect on systemic immunity. Materials and Methods: This single-center retrospective study was approved by the Institutional Review Board. From August 1, 2019, to March 30, 2021, patients with uHCC who received the combination therapy of TACE+ICIs+TKIs were included. Peripheral blood samples were collected at baseline and once a month for 4 months after treatment. Lymphocyte subsets were measured by flow cytometry. Immunoglobulins were measured using the immune turbidimetric method. The dynamic change trend of circulating parameters was tested using simple linear regression. Results: Fifty-three patients with a mean age of 59 ± 10.6 years were included. TTP was 8.0 months (95% CI, 5.5-10.5) and PFS was 8.5 months (95% CI, 5.4-11.5). ORR was 52.8% and DCR was 81.1%. Twenty patients had completed analysis of biomarkers in peripheral blood. For cellular immune response, the level of circulating CD8+, CD3+ T cells and NK cells increased, the frequency of CD4+T cells and the CD4+/CD8+ ratio decreased, and among them, CD8+ T cells increased significantly. For humoral immune response, there was a significant decrease in B cells and a significant increase in Ig G, Ig κ, and Ig λ. Moreover, Ig G, Ig κ, and Ig λ were related to tumor response. Conclusion: TACE+ICIs+TKIs showed considerable efficacy in patients with uHCC. This triple therapy activated not only cell immune but also humoral immune activation. Circulating Ig G, Ig λ, and Ig κ can serve as potential biomarkers.


Subject(s)
Carcinoma, Hepatocellular , Chemoembolization, Therapeutic , Liver Neoplasms , Aged , CD8-Positive T-Lymphocytes/pathology , Carcinoma, Hepatocellular/pathology , Chemoembolization, Therapeutic/adverse effects , Chemoembolization, Therapeutic/methods , Humans , Immune Checkpoint Inhibitors/therapeutic use , Immunity , Liver Neoplasms/pathology , Middle Aged , Protein Kinase Inhibitors/therapeutic use , Retrospective Studies
14.
Cancer Cell Int ; 21(1): 212, 2021 Apr 15.
Article in English | MEDLINE | ID: mdl-33858418

ABSTRACT

BACKGROUND: Epithelial-mesenchymal transition (EMT) has been associated with wound healing, tumorigenesis, and metastasis. Circular RNAs (circRNAs) are functional non-coding RNAs involved in multiple human cancers. However, whether and how circRNAs contribute to the EMT in hepatocellular carcinomas (HCC) remains to be deciphered. In this study, we investigated the regulation and function of hsa_circ_0003288 on programmed death-1 ligand 1 (PD-L1) during EMT and HCC invasiveness. METHODS: Hsa_circ_0003288 expression was measured by real-time quantitative reverse transcriptase PCR (qRT-PCR). Luciferase reporter assays, RNA pull-down assay and fluorescence in situ hybridization (FISH) were used to determine the correlation between hsa_circ_0003288 and miR-145 and between miR-145 and PD-L1. Furthermore, ectopic overexpression and siRNA-mediated downregulation of hsa_circ_0003288, transwell assays, and in vivo studies were used to determine the function of hsa_circ_0003288 on the EMT and invasiveness of L02 and HCC cells. RESULTS: miR-145 directly targeted the PD-L1 3'-untranslated region (UTR) region, and hsa_circ_0003288 acted as a miR-145 sponge to regulate PD-L1 expression. Overexpression of hsa_circ_0003288 increased PD-L1 levels and promoted EMT, migration, and invasiveness of L02 cells. These observations were reversed after knockdown of hsa_circ_0003288 in HepG2 and Huh7 cells. Overexpression of PD-L1 rescued EMT, migration, and invasiveness of HepG2 and Huh7 cells after knockdown of hsa_circ_0003288. Furthermore, hsa_circ_0003288 knockdown reduced EMT in in vivo studies. Hsa_circ_0003288/PD-L1 axis was found to mediate the metastatic phenotypes via the PI3K/Akt pathway in HCC. Additionally, expression levels of hsa_circ_0003288 were increased and positively correlated with PD-L1 expression in HCC tissues. CONCLUSION: Our findings demonstrated that hsa_circ_0003288 promoted EMT and invasion of HCC via the hsa_circ_0003288/miR-145/PD-L1 axis through the PI3K/Akt pathway. Targeting hsa_circ_0003288 may be a therapeutic strategy for the treatment of HCC.

15.
IEEE Trans Image Process ; 30: 1030-1043, 2021.
Article in English | MEDLINE | ID: mdl-33232236

ABSTRACT

This paper proposes a regularized blind deconvolution method for restoring Poissonian blurred image. The problem is formulated by utilizing the L0 -norm of image gradients and total variation (TV) to regularize the latent image and point spread function (PSF), respectively, and combining them with the negative logarithmic Poisson log-likelihood. To solve the problem, we propose an approach which combines the methods of variable splitting and Lagrange multiplier to convert the original problem into three sub-problems, and then design an alternating minimization algorithm which incorporates the estimation of PSF and latent image as well as the updation of Lagrange multiplier into account. We also design a non-blind deconvolution method based on TV regularization to further improve the quality of the restored image. Experimental results on both synthetic and real-world Poissonian blurred images show that the proposed method can achieve restored images of very high quality, which is competitive with or even better than some state of the art methods.

16.
Gastroenterol Rep (Oxf) ; 8(5): 390-398, 2020 Oct.
Article in English | MEDLINE | ID: mdl-33163195

ABSTRACT

BACKGROUND: The epithelial-to-mesenchymal transition (EMT) status is associated with programmed death-1 ligand 1 (PD-L1) expression in various cancers. However, the role and molecular mechanism of PD-L1 in the EMT of sorafenib-resistant hepatocellular carcinoma (HCC) cells remain elusive. In this study, we aimed to investigate the regulation of PD-L1 on the EMT in sorafenib-resistant HCC cells. METHODS: Initially, the sorafenib-resistant HCC cell lines HepG2 SR and Huh7 SR were established. Western-blot assays were used to detect the expression of PD-L1, E-cadherin, and N-cadherin. The intervention and overexpression of PD-L1 were used to explore the role of PD-L1 in the regulation of EMT in HepG2 SR and Huh7 SR cells. Cell migration and invasion were assessed by transwell assays. PD-L1 or Sterol regulatory element-binding protein 1 (SREBP-1) overexpression and knock-down were performed in order to study the mechanism of PD-L1 in sorafenib-resistant HCC cells. RESULTS: PD-L1 expression was upregulated, whereas E-cadherin levels were downregulated and N-cadherin expression was increased in HepG2 SR and Huh7 SR cells. The cell viabilities of HepG2 and Huh7 cells were lower than those of HepG2 SR and Huh7 SR cells. PD-L1 overexpression reduced E-cadherin expression and increased N-cadherin levels, whereas PD-L1 knock-down increased E-cadherin expression and decreased N-cadherin expression. PD-L1 expression promoted EMT and the migratory and invasive abilities of HepG2 SR and Huh7 SR cells. PD-L1 promoted the EMT of sorafenib-resistant HCC cells via the PI3K/Akt pathway by activating SREBP-1 expression in HepG2 SR and Huh7 SR cells. CONCLUSIONS: The findings reveal that PD-L1 expression promotes EMT of sorafenib-resistant HCC cells.

17.
Pharmacopsychiatry ; 52(5): 222-231, 2019 Sep.
Article in English | MEDLINE | ID: mdl-30485867

ABSTRACT

BACKGROUND: The association between CYP2D6 metabolizer status and clinical outcomes of venlafaxine was extensively investigated previously, but no widely accepted conclusion has been reached so far. To obtain a more precise estimation of the association, a systematic review by meta-analysis was conducted in the present study. METHODS: The PubMed, EMBASE, Cochrane Library, Chinese National Knowledge Infrastructure, Technology of Chongqing, and Wan Fang Database were searched for eligible studies up to August 2018. RESULTS: Fourteen related studies involving 1035 patients were finally included. Significant associations were found among 3 CYP2D6 phenotypes (NM, IM, and PM) and most pharmacokinetic parameters of venlafaxine. However, CYP2D6 phenotypes were not associated with Hamilton Depression Rating Scale response of venlafaxine. In addition, we also found no significant association between CYP2D6 phenotype and overall rate of adverse events. CONCLUSIONS: CYP2D6 metabolizer status had significant influence on venlafaxine pharmacokinetics, but insufficient evidence demonstrated that CYP2D6 metabolizer status was associated with its therapeutic effects and overall rate of adverse events, which provided further evidence regarding the relationship between CYP2D6 metabolizer status and venlafaxine.


Subject(s)
Cytochrome P-450 CYP2D6/genetics , Depression/drug therapy , Venlafaxine Hydrochloride/pharmacokinetics , Venlafaxine Hydrochloride/therapeutic use , Antidepressive Agents, Second-Generation/therapeutic use , Humans , Treatment Outcome , Venlafaxine Hydrochloride/adverse effects
18.
Mol Med Rep ; 18(6): 5087-5094, 2018 12.
Article in English | MEDLINE | ID: mdl-30272313

ABSTRACT

Pancreatic cancer (PaC) is an aggressive malignancy, which is associated with high levels of metastasis. Circulating tumor cells (CTCs), which may be considered a functional biomarker and promising treatment strategy for metastasis, are associated with the prognosis and progression of various metastatic cancers, including PaC. Receptor tyrosine kinase­like orphan receptor 1 (ROR1) expression contributes to cell metastasis and poor clinical outcomes in malignant tumors. The present study aimed to explore the function of ROR1 in PaC CTCs. Reverse transcription­quantitative polymerase chain reaction and western blot analysis were used to examine the expression of ROR1, E­cadherin and N­cadherin. Cell proliferative and invasive ability was assessed by MTT and Transwell assays, respectively. The results revealed that the mRNA and protein expression levels of ROR1 were augmented in PaC tissues. Furthermore, the mRNA expression levels of ROR1 were higher in CTCs compared with in peripheral blood cells, and ROR1 was more highly expressed in CTCs than in cells. Notably, CTCs exhibited a markedly greater proliferative and invasive capacity than PANC­1 and SW­1990 cells, whereas knockdown of endogenous ROR1 by small interfering RNA led to suppression of the invasion of CTCs. In addition, it was revealed that the mechanism underlying the effects of ROR1 on PaC CTC metastasis may involve the epithelial­mesenchymal transition process. In conclusion, ROR1 may be considered a potential biomarker and therapeutic target for the treatment of PaC.


Subject(s)
Gene Expression Regulation, Neoplastic , Neoplastic Cells, Circulating/metabolism , Pancreatic Neoplasms/genetics , Receptor Tyrosine Kinase-like Orphan Receptors/genetics , Adult , Biomarkers, Tumor , Cell Line, Tumor , Epithelial-Mesenchymal Transition/genetics , Female , Gene Knockdown Techniques , Humans , Male , Middle Aged , Neoplasm Invasiveness , Pancreatic Neoplasms/pathology
19.
Int J Nanomedicine ; 13: 763-776, 2018.
Article in English | MEDLINE | ID: mdl-29440899

ABSTRACT

INTRODUCTION: The toxic side effects of doxorubicin (DOX) have limited its use in chemotherapy. Neither liposomal DOX nor pegylated liposomal DOX are able to completely resolve this issue. This is a proof-of-concept study testing aptamer-drug conjugate (ApDC) targeted delivery systems for chemotherapeutic drugs. METHODS: Aptamer library targeting human epidermal growth factor receptor 3 (HER3) was screened and affinity was determined by enzyme-linked immunosorbent assay. Specificity was tested in MCF-7HER3-high, BT474HER3-high, and 293THER3-negative cells using flow cytometry and confocal microscopy. We further developed a HER3 aptamer-functionalized liposome encapsulating DOX and the efficiency of this ApDC was detected by cellular uptake analysis and cell viability assay. In MCF-7 tumor-bearing mice, tumor targeting evaluation, efficacy, toxicity and preliminary pharmocokinetic study was performed. RESULTS: The candidate #13 aptamer had highest affinity (Kd =98±9.7 nM) and specificity. ApDC effectively reduces the half maximal inhibitory concentration of DOX compared with lipsome-DOX and free DOX. In vivo imaging and preliminary distribution studies showed that actively targeted nanoparticles, such as Apt-Lip-DOX molecules, could facilitate the delivery of DOX into tumors in MCF-7-bearing mice. This targeted chemotherapy caused greater tumor suppression than other groups and alleviated side effects such as weight loss, low survival rate, and organ (heart and liver) injury demonstrated by H&E staining. CONCLUSION: The results indicate that targeted chemotherapy using the aptamer-drug conjugate format could provide better tolerability and efficacy compared with non-targeted delivery in relatively low-dose toxic drugs.


Subject(s)
Aptamers, Nucleotide/metabolism , Cardiotoxicity/etiology , Doxorubicin/administration & dosage , Drug Delivery Systems/methods , Nanoparticles/administration & dosage , Receptor, ErbB-3/metabolism , Animals , Antibiotics, Antineoplastic/administration & dosage , Antibiotics, Antineoplastic/adverse effects , Antibiotics, Antineoplastic/pharmacokinetics , Cell Line, Tumor , Cell Survival/drug effects , Doxorubicin/adverse effects , Doxorubicin/analogs & derivatives , Doxorubicin/pharmacokinetics , Enzyme-Linked Immunosorbent Assay , Female , Humans , Liposomes/chemistry , MCF-7 Cells , Mice, Inbred BALB C , Nanoparticles/chemistry , Nanoparticles/toxicity , Polyethylene Glycols/administration & dosage , Polyethylene Glycols/adverse effects , Tissue Distribution , Xenograft Model Antitumor Assays
20.
Eur J Clin Pharmacol ; 74(4): 433-442, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29243113

ABSTRACT

PURPOSE: Valproic acid (VPA) is one of the most widely used antiepileptic drugs. Recently, increasing evidence suggested that polymorphisms in UGT2B7 gene were associated with VPA pharmacokinetics, but results remained controversial. Therefore, a meta-analysis was performed to derive a more precise evaluation between C802T, C161T, and G211T polymorphisms and plasma concentration of VPA. METHODS: The PubMed, EMBASE, and the Cochrane library databases were searched for eligible studies. Articles meeting the inclusion criteria were comprehensively reviewed, and the available data were accumulated. The mean difference (MD) and 95% confidence interval (CI) were applied to assess the strength of the relationship. RESULTS: A total of 12 studies involving 1996 related East Asia epilepsy patients were assessed. We found that the UGT2B7 G211T polymorphism was associated with adjusted plasma VPA concentration (GG versus TT: P = 0.01, I 2 = 97%; GG versus GT: P < 0.00001, I 2 = 0%). Additionally, we also observed a significantly association between the C161T polymorphism and adjusted plasma VPA concentration (CC versus CT: P = 0.01, I 2 = 77%). Nevertheless, the pooled analysis showed that the C802T polymorphism had no significant effect on adjusted serum concentration of VPA. CONCLUSIONS: The results of this meta-analysis demonstrated that UGT2B7 G211T and C161T polymorphisms were able to affect the pharmacokinetics in epilepsy patients treated with VPA, which provide further evidence for genetic effects of UGT2B7 gene on pharmacokinetics and pharmacodynamics of VPA. Epilepsy patients with these genotypes may be necessary to increase (or decrease) VPA dose to ensure its therapeutic effect.


Subject(s)
Anticonvulsants/blood , Epilepsy/drug therapy , Glucuronosyltransferase/genetics , Pharmacogenomic Variants , Polymorphism, Genetic , Valproic Acid/blood , Anticonvulsants/administration & dosage , Anticonvulsants/pharmacokinetics , Chi-Square Distribution , Epilepsy/blood , Epilepsy/diagnosis , Gene Frequency , Glucuronosyltransferase/metabolism , Heterozygote , Homozygote , Humans , Pharmacogenetics , Phenotype , Valproic Acid/administration & dosage , Valproic Acid/pharmacokinetics
SELECTION OF CITATIONS
SEARCH DETAIL
...